Modality
Peptide
MOA
IL-13i
Target
PARP
Pathway
DDR
PVPTSD
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
Nov 2019
→ Jul 2027
Phase 2Current
NCT06022956
1,963 pts·PTSD
2019-11→2027-07·Terminated
1,963 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-121.3y awayPh3 Readout· PTSD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2027-07-12 · 1.3y away
PTSD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06022956 | Phase 2/3 | PTSD | Terminated | 1963 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |